Abstracts tagged "Economics"

Abstract Number: 1018 • ACR Convergence 2024
Analysis of Medication Usage and Monthly Costs in Hospitalized Patients with Rheumatic Diseases: A Retrospective Observational Study
Daniela Alejandra Salcedo-Soto¹, Ana Cecilia Bardan-Inchaustegui², Pablo Gamez-Siller³, Deynna Montserrat Lara Mendez⁴, Diana Elsa Flores-Alvarado⁵, Jorge Esquivel-Valerio⁶, Jesus Cardenas-de la Garza² and Dionicio Galarza-Delgado⁷, ¹Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, ⁵Hospital Universitario Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Costs associated with rheumatic diseases significantly affect a considerable portion of patients’ income. The monthly income of northeastern Mexican families has been reported to…
Abstract Number: 1046 • ACR Convergence 2024
Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology
Katherine Schoeffler, Stephanie Beveridge, Max Bouvette, Veera Durga Vaishnavi Kurra, Reema Moussa, Ryan Johnson, Camille Goerend, Nimrah Bader and Ryan Nipp, University of Oklahoma College of Medicine, Oklahoma City, OK

Background/Purpose: Recent policy changes and competitive alternative drug pricing models present the potential for medication cost savings. In this study, we sought to assess the…
Abstract Number: 1049 • ACR Convergence 2024
Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology
Eric Roberts¹, Gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: In 2021, over 300,000 patients in the United States used adalimumab, making it one of the highest-grossing drugs globally. In 2023, patent exclusivity for…
Abstract Number: 1870 • ACR Convergence 2024
Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France
Nicoleta Petrica¹, Nathan Cohen¹, Maria Pini¹, Minjee Park², Mathieu Rosé³ and Jean-Francois Ricci², ¹Alira Health, Paris, France, ²Alira Health, Basel, Switzerland, ³Alira Health, Barcelone, Spain
Background/Purpose: Lupus, a rare chronic autoimmune disorder, severely impacts patients' quality of life, productivity, and survival, placing a heavy burden on the healthcare system. Up…
Abstract Number: 1904 • ACR Convergence 2024
Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level
Wilson Bautista-Molano¹, Ingrid Ramirez-bolivar², Cristina Pinilla-Forero³ and Luz A Ruiz⁴, ¹University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, ²Janssen, Bogotá, Colombia, ³Janssen, Bogotá, ⁴CODENTMED, Bogotá, Colombia
Background/Purpose: Psoriatic arthritis (PsA) is a high-cost disease due to its significant impact on patients' quality of life and the extensive resources required for its…
Abstract Number: 2609 • ACR Convergence 2024
Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry
Eric Roberts¹, Nick Bansback², Chien-Wen Tseng³, Steve Shiboski⁴, Jing Li⁵, Gabriela Schmajuk⁶ and Jinoos Yazdany⁷, ¹University of California, San Francisco, SF, CA, ²University of British Columbia, Vancouver, BC, Canada, ³University of Hawai'i John A. Burns School of Medicine, Honolulu, ⁴University of California, San Francisco, San Francisco, ⁵University of California, San Francisco, San Francisco, CA, ⁶UCSF / SFVA, San Francisco, CA, ⁷UCSF, San Francisco, CA
Background/Purpose: Biosimilars hold promise for reducing pharmaceutical expenditures, however uptake has lagged. We analyzed the variability in new biosimilar starts and switching from bio-originator infliximab…
Abstract Number: 2682 • ACR Convergence 2024
The Forgotten Costs of SLE: Estimating Indirect Costs in a National SLE Cohort
Ann E. Clarke¹, Yvan St-Pierre², Megan Barber¹, Sasha Bernatsky³, Evelyne Vinet⁴, Christian Pineau⁵, Murray Urowitz⁶, Dafna Gladman⁷, Christine Peschken⁸, John Hanly⁹, Alexandra Legge¹⁰ and Paul Fortin¹¹, ¹Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²McGill University Health Center, Montreal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Centre, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶Self employed, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ¹⁰Dalhousie University, Halifax, NS, Canada, ¹¹Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Economic analyses of SLE often include only direct healthcare costs. Indirect costs, particularly those attributable to lost productivity in unpaid labour, are often overlooked,…
Abstract Number: 0212 • ACR Convergence 2024
Costs of Hospitalization in Patients with SLE: An Analysis of the National Inpatient Sample
Brandon Blau¹, Kelsey Gripp¹, Catherine MacLean² and Bella Mehta², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with significant health care utilization, medical costs, and increased risk of hospitalization. We aimed to characterize the reasons…
Abstract Number: 0120 • ACR Convergence 2023
Incidence and Prevalence of Systemic Lupus Erythematosus in Urban China, 2013-2017: A Nationwide Population-based Study
Mucong Li¹, Chaiquan Li², Mengzhuo Cao³, Ke Lu², Chanyuan Wu³, Jiuliang zhao¹, Qian Wang⁴, Xinping Tian¹, Xun Tang², Mengtao Li¹, xiaofeng Zeng⁴ and Pei Gao², ¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Peking University, Beijing, China, ³Peking Union Medical College Hospital, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Systemic lupus erythematosus (SLE) is becoming a public health concern because of increasing disease and economic burdens. Epidemiological information on SLE, especially its incidence…
Abstract Number: 0155 • ACR Convergence 2023
Cost Analysis of Subcutaneous Methotrexate Compared to Oral Methotrexate Treatment for Rheumatoid Arthritis
Aniket Kawatkar, David Yi, Erika Estrada and Cecilia Portugal, Kaiser Permanente Southern California, Pasadena, CA
Background/Purpose: Rheumatoid Arthritis (RA)patients who switch from oral to subcutaneous methotrexate (MTX) may experience better response to treatment due to increased bioavailability, enhanced tolerability, increased…
Abstract Number: 0159 • ACR Convergence 2023
Understanding the Economic Impact of Autoimmune Eye Disease in the United States
Krati Chauhan¹, Steven Scaife² and Michael Buhnerkempe¹, ¹Southern Illinois University - School of Medicine, Springfield, IL, ²Southen Illinois University - School of Medicine., Springfield, IL
Background/Purpose: Eye involvement is an important cause of morbidity in rheumatology patients. Inflammatory eye diseases include conditions like scleritis, uveitis, retinitis and orbital inflammation. The…
Abstract Number: 0166 • ACR Convergence 2023
Annual Economic Burden for Patients with Familial Hypophosphatemia in the United States
Zhiyi Li¹, Elizabeth Marchlewicz², Danae Black², Hana Schwartz², Yang Zhao¹ and Erik Imel³, ¹Kyowa Kirin North America, Bedminster, NJ, ²Merative, Cambridge, MA, ³Indiana University School of Medicine, Indianapolis, IN
Background/Purpose: Familial hypophosphatemia (FH) is most commonly due to phosphate regulating endopeptidase X-linked (PHEX) gene mutations resulting in renal phosphate wasting, which leads to rickets,…
Abstract Number: 0168 • ACR Convergence 2023
What Are the Characteristics of a Cost-Effective Psoriatic Arthritis Biomarker Test? An Early Health Technology Assessment
Nick Bansback¹, Alex Tam², Dafna Gladman³, Vathany Kulasingam⁴, Eldon Spackman⁵ and Vinod Chandran⁶, ¹University of British Columbia, Vancouver, BC, Canada, ²Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁴Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Initiating treatment in patients with psoriasis (PsO) who have unrecognized Psoriatic arthritis (PsA) may slow disease progression and improve long-term outcomes. Several candidate biomarkers…
Abstract Number: 0169 • ACR Convergence 2023
Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective
Alejandro Figueroa-Lara¹, Mary Ann Aure² and Carmen Andalucia¹, ¹Werfen, San Diego, CA, ²Werfen, Chula Vista, CA
Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) is a subgroup of immune-mediated myopathies (IMM). The diagnosis of IMNM relied on the presence of proximal muscle weakness, high…
Abstract Number: 0173 • ACR Convergence 2023
Review of Published Literature Reporting Economic Burden of Treatment Switching in Rheumatoid Arthritis
Peter C. Taylor¹ and Jenya Antonova², ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Compass Strategy and Research, Inc., San Francisco, CA
Background/Purpose: For rheumatoid arthritis (RA) American College of Rheumatology (ACR) recommends the treating to target approach, starting with conventional synthetic antirheumatic drugs (DMARDs). ACR advises…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].